September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Early intravitreal triamcinolone acetonide for persistent diabetic macular edema after vitrectomy.
Author Affiliations & Notes
  • Masahiko Sugimoto
    Ophthalmology, Mie University School of Medicine, Tsu, Mie, Japan
  • Mineo Kondo
    Ophthalmology, Mie University School of Medicine, Tsu, Mie, Japan
  • Atsushi Ichio
    Ophthalmology, Mie University School of Medicine, Tsu, Mie, Japan
  • Footnotes
    Commercial Relationships   Masahiko Sugimoto, None; Mineo Kondo, None; Atsushi Ichio, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3279. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Masahiko Sugimoto, Mineo Kondo, Atsushi Ichio; Early intravitreal triamcinolone acetonide for persistent diabetic macular edema after vitrectomy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3279.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine whether intravitreal triamcinolone acetonide (IVTA) is effective in resolving the edema in eyes with persistent diabetic macular edema (DME) after vitrectomy.

Methods : Sixteen eyes of 16 patients were given 4 mg IVTA after vitrectomy for DME. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and average threshold (AT) of the central retina were determined during the 24 weeks follow-up period. Patients were divided into two groups; early treated group and late treated group.

Results : The BCVA was significantly improved from 0.61±0.06 (pre treatment) to 0.53 ±0.03 (12week), the CMT was significantly improved from 412.6±37.1μm(pretreatment) to 342.5±31.3 (24week) , and the AT was significantly improved from 16.2±1.7 dB(pre treatment) to 17.0±1.6 (4week) after IVTA (repeated ANOVA, P<0.05). The BCVA was a significantly improved for early treated group than late treated group at 4 and 12 weeks (unpaired t test, P<0.05).

Conclusions : Our results indicate that IVTA should be considered for treatment of patients with persistent DME after vitrectomy, especially with early treated group.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×